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Reprogramming can occur by the introduction of key transcription factors (TFs) as well as by epigenetic changes.We demonstrated
that histone deacetylase inhibitor (HDACi) Trichostatin A (TSA) combined with a chromatin remodeling medium (CRM)
induced expression of a number of definitive endoderm and early and late pancreatic marker genes. When CRM was omitted,
endoderm/pancreatic marker genes were not induced. Furthermore, treatment with DNA methyltransferase inhibitor (DNMTi)
5-azacytidine (5AZA) CRM did not affect gene expression changes, and when 5AZA was combined with TSA, no further increase
in gene expression of endoderm, pancreatic endoderm, and endocrine markers was seen over levels induced with TSA alone.
Interestingly, TSA-CRM did not affect expression of pluripotency and hepatocyte genes but induced some mesoderm transcripts.
Upon removal of TSA-CRM, the endoderm/pancreatic gene expression profile returned to baseline. Our findings underscore the
role epigenetic modification in transdifferentiation of one somatic cell into another. However, full reprogramming of fibroblasts to
𝛽-cells will require combination of this approach with TF overexpression and/or culture of the partially reprogrammed cells under
𝛽-cell specific conditions.
1. Introduction
Type-1 diabetes mellitus (DM-I) is a severe metabolic disease
that affectsmillions of people worldwide. It involves complete
loss of functional insulin secreting 𝛽-cells in the pancreas due
to autoimmune destruction. DM-1 leads to hyperglycemia,
which can be treated with insulin injections. However, in
the long term, DM-1 leads to micro- and macrovascular,
cardiovascular, neuronal, renal, and ocular complications due
to intermittent hyperglycemia. Replacement of the destroyed
𝛽-cells is the only curative treatment. However, limited
numbers of available donor organs and immunological issues
restrict whole pancreas or islet transplantation [1, 2]. An
alternative source for human cadaveric islets is generating
insulin-producing 𝛽-cells from stem cells and/or somatic
cells. However, the challenge in this area is to identify an
adequate stem or progenitor cells and mechanisms to create
a safe source of mature insulin-producing 𝛽-cells from such
cells.
Over the last decade, several studies have demonstrated
that it is possible to generate functional 𝛽-cells from human
embryonic stem cells (hESCs) by culturing the cells in
conditions that mimic in vivo pancreatic development [3–
6]. With the advent of induced pluripotent stem cells
(iPSCs) technology, developed by the Yamanaka team [7,
8], it has now also become possible to create Human
Leukocyte Antigen- (HLA-) identical 𝛽-cells to treat DM-I.
However, the pluripotent nature of ESCs and iPSCs leaves
the possibility for teratoma formation [6, 9], if full dif-
ferentiation towards 𝛽-cells is not achieved. An alternative
approach is to transdifferentiate somatic cells into insulin-
producing 𝛽-cells without passing through a pluripotent
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state, via ectopic expression of defined TFs and culture in
supportive medium. A number of studies demonstrated in
rodents that introduction of a single (PDX1) or group of
TFs (PDX1, NGN3, and MAFA) can transdifferentiate hepa-
tocytes, intestinal cells, exocrine acinar or ductal pancreatic
cells, or endocrine 𝛼-cells, thereby reprogramming these
non-𝛽-cell endodermal cells into 𝛽-cells [10–17]. In addition,
Li et al. created endodermal progenitor cells by transiently
overexpressing OCT4, SOX2, KLF4, and CMYC (OKSM) in
mouse embryonic fibroblasts (MEFs) combined with small
molecule epigenetic modifiers, which could subsequently
be converted to 𝛽-cells [18]. Several recent studies have
treated human or swine fibroblasts [19–21], mesenchymal
stem cells [22], or rat liver stem cells [23], with epige-
neticmodifyingmolecules (DNAmethyltransferase inhibitor
and/or histone deacetylase inhibitor) in CRM followed by
culture under 𝛽-cell specifying conditions. This combined
treatment resulted in the generation of endocrine pancre-
atic 𝛽-cells that reversed hyperglycemia in immunodeficient
mice. Moreover, epigenetic modification also induced NGN3
expression and endocrine differentiation of the PNAC-1
human ductal cell line [24]. However, many studies reported
that TSA itself could induce chromatin changes without
the presence of chromatin remodeling medium (CRM).
For instance, using fluorescence anisotropy imaging and
fluorescence recovery after photobleaching (FRAP) and fluo-
rescence correlation spectroscopy (FCS), it was demonstrated
that TSA induced histone protein dynamics and expres-
sion in HeLa cells by increasing the euchromatin fraction
and increasing core acetylation patterns, phosphorylation
patterns, and nuclear volume [25]. Similarly, TSA induces
histone acetylation and reversible decondensation of inter-
phase chromatin structure in HeLa cells, as demonstrated by
image correlation spectroscopy (ICS) and spatially resolved
scaling analysis (SRSA) methods [26]. Furthermore, treat-
ment with TSA and VPA (valproic acid) increased the active
chromatin marks, such as H3K9ac and H3K4me2 abun-
dance, which might lead to chromatin decondensation in
human hepatocellular carcinoma (HepG2) andNIH 3T3 cells
[27, 28].
We here optimized the exposure of human fibroblasts
to epigenetic modifiers to convert them to endoderm and
pancreatic endocrine progenitors.We demonstrated that cul-
ture of adult human and foreskin fibroblasts with TSA com-
bined with a chromatin remodeling medium (CRM) induces
expression of endoderm and pancreatic endoderm genes but
that this is a transient phenomenon. Hence, further mainte-
nance in 𝛽-cell-specifying conditions with or without forced
expression of exogenous TFs will be needed to permanently
convert fibroblasts to 𝛽-cells.
2. Materials and Methods
2.1. Culture of BJ1 Human Fibroblasts. Human BJ1 adult
fibroblasts were cultured in 90% DMEM-F12 + HEPES (Life
Technologies, NY, USA), 10% Fetal Bovine Serum (FBS,
HyClone, USA), and 1% Penicillin/Streptomycin (Life Tech-
nologies). Cells weremaintained under normoxic conditions,
37∘C temperature, and 5% CO
2
.
2.2. Isolation and Culture of Primary Human Fibroblasts.
A skin biopsy from healthy volunteer/nondiabetic donor
was obtained following informed consent and with approval
from the ethical committee of University of KU Leuven.
Fibroblasts were isolated in minimumDMEM supplemented
with 20% FBS. After four passages, fibroblasts were frozen in
liquid nitrogen in several aliquots. After thawing cells were
grown in 90% DMDM HG + Glutamax (Life Technologies),
supplemented with 10% FBS and 1% Penicillin/Streptomycin
(Life Technologies). Cells were maintained under normoxic
conditions, 37∘C temperature, and 5% CO
2
.
2.3. Reprogramming Conditions. Chromatin remodeling me-
dium (CRM) consisted of 10% knockout (KO) serum, KO-
DMEM, 50mM 𝛽-mercaptoethanol, 1% nonessential amino
acids, 1% B27 supplement, 2mM L-glutamine, and 2%
N2 supplement, all from Life Technologies, and 20 ng/mL
fibroblast growth factor (Peprotech, USA), 20 ng/mL epider-
mal growth factor (R&D Systems, MN, USA), 1000U/mL
Penicillin/Streptomycin (Life Technologies), and 100 nM L-
Ascorbic Acid (Sigma Aldrich). Cells were plated in 6-well
plate (VWR, MA, USA) and exposed to 3𝜇M or 5𝜇M
5AZA (Sigma Aldrich, dissolved in DMSO) in CRMmedium
for 48 hours, with medium change at 24 h. For treatment
with Trichostatin A (TSA), ready-made solution 5mM
(SigmaAldrich), cells were exposed to various concentrations
between 100 nM and 100 𝜇M for 24 hours. Untreated fibrob-
lasts and DMSO treated fibroblasts cultured in CRM were
used as controls.
2.4. RNA Isolation, cDNA Synthesis, and Quantitative Real-
Time Polymerase Chain Reaction (qRT-PCR). Total RNA was
extracted usingGenEluteMammalian Total RNAMiniprep
Kit (Sigma Aldrich); for sample size < 105 cells, ZR RNA
Microprep CA, USA, was used and cDNA was synthesized
from 1 𝜇g total RNA using superscript III reverse transcrip-
tase (Life Technologies) both according to manufacturer’s
protocol. For qPCR, the cDNA underwent 40 rounds of
amplification cycles on a ViiA 7 Real-Time PCR System
(Applied Biosystems) as follows: 40 cycles of a 2-step PCR
(95∘C for 15 sec, 60∘C for 45 sec) after initial denaturation
(50∘C for 2min, 95∘C for 2min) using specific primers,
Platinum SyBR Green qPCR SuperMix-UDG (Life Tech-
nologies), and 2 𝜇L cDNA. For normalization purposes,
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was
used as a housekeeping control and results are shown in
relative expression to GAPDH. All primers were synthesized
at IDT Technologies, Belgium.The cycle threshold value > 40
is considered undetectable and calculated as Ct of 40. A list
of the primers can be found in Table 1.
2.5. Statistical Analysis. Parametric distribution of data
points was confirmed using the Kolmogorov-Smirnov test.
Comparisons between two groups were analyzed using an
unpaired 2-tailed Student’s 𝑡-test. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and
∗∗∗𝑝 < 0.001 were considered significant. Data are shown as
mean and error bars represent standard error of mean (SEM)
of minimum three independent experiments. All results were
analyzed using Graph Pad prism 6 software.
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Table 1: Primers sets used for gene expression analysis by qRT-PCR.
Gene Forward Reverse
GAPDH TCAAGAAGGTGGTGAAGCAGG ACCAGGAAATGAGCTTGACAAA
GATA4 TCCAAACCAGAAAACGGAAG CTGTGCCCGTAGTGAGATGA
SOX7 GCCTGTGCAACAAGAGTGAA GTACCCTGGGTCTTTGGTCA
MIXL1 GGATCCAGGTATGGTTCCAG CATGAGTCCAGCTTTGAACC
GSC TCTCAACCAGCTGCACTGTC CCAGACCTCCACTTTCTCCTC
EOMES AACAACACCCAGATGATAGTC TCATAGTTGTCTCTGAAGCCT
E-CADHERIN CGAACTATATTCTTCTGTGAGAGG GATAGATTCTTGGGTTGGGTC
SOX17 CGCTTTCATGGTGTGGGCTAAGGACG TAGTTGGGGTGGTCCTGCATGTGCTG
FOXA2 AGGAGGAAAACGGGAAAGAA GGTGCTTGAAGAAGCAGGAG
CXCR4 CACCGCATCTGGAGAACCA GCCCATTTCCTCGGTGTAGTT
HNF1B TCACAGATACCAGCAGCATCAGT GGGCATCCCAGGCTTGTA
SOX9 ACGCCATCTTCAAGGCGCTG CCGGCTGCACGTCGGTTTT
PTF1A ACGACTTCTTCACCGACCAG TGGTGGCTAAGGAACTCCAC
PDX1 TCCACCTTGGGACCTGTTTA GTGTGTTAGGGAGCCTTCCA
HLXB9 ATGATCCTGCCTAAGATGCC AAATCTTCACCTGGGTCTCG
PAX6 CCCAAGAGCAAATTGAGGCCC CTCTTCTCCATTTGGCCCTTCGA
NKX6.1 CTTCCCGTCTTTGTCCAACAA CCATCTTCTGGCCCGGAGTGA
NEUROD1 TAAGACGCAGAAGCTGTCCA CTGCTCAGGCAGAAAAGTCC
ISL1 GTACAACCACCATTTCACTG CCCGTACAACCTGATATAATCTC
ARX ACAGCGTGTGCCTCTCTGC TCGGGCCTCGGTCAAGTCC
PAX4 CAACCGAGTCCTGCGGGCAT GCCAGCTTTCCACGGGCCAC
NGN3 TCTCTATTCTTTTGCGCCGG CTTGGACAGTGGGCGCAC
MAFB GCCTGCGCTAATTGTAGGAG CAAAAGCAGGGAAAGAAACG
MAFA TCATCCGGCTCAAGCAGAAG TCTCGCTCTCCAGAATGTGC
INS ATCAAGCACATCACTGTCCT TGTAGAAGAAGCCTCGTTCC
SST GAGGCTTGAGCTGCAGAGAT TCGCTGAAGACTTGGAGGAT
GCG GTTCCCTTCAAGACACAGAG GGCAATGTTATTCCTGTTCC
MYOD1 CGACGGCATGATGGACTACA TAGTAGGCGCCTTCGTAGCA
TIE2 TGCCCAGATATTGGTGTCCT CTCATAAAGCGTGGTATTCACGTA
FLK1 ACAACCAGACGGACAGTGGT AGCCTTCAGATGCCACAGAC
VE-CADHERIN GTTCACGCATCGGTTGTTC TCTGCATCCACTGCTGTCA
ALB ATGCTGAGGCAAAGGATGTC AGCAGCAGCACGACAGAGTA
AFP TGAGCACTGTTGCAGAGGAG GTGGTCAGTTTGCAGCATTC
HNF4A ACTACGGTGCCTCGAGCTGT GGCACTGGTTCCTCTTGTCT
OCT4 GATGGCGTACTGTGGGCCC TGGGACTCCTCCGGGTTTTG
SOX2 TGGCGAACCATCTCTGTGGT CCAACGGTGTCAACCTGCAT
NANOG CCTGTGATTTGTGGGCCTG GACAGTCTCCGTGTGAGGCAT
3. Results
3.1. Treatment of Human Primary Adult and Foreskin BJ1
Fibroblasts with TSA Induced Definitive Endoderm and Pan-
creatic Endocrine Genes but Only Transiently. We initially
tested the effect of addition of the HDAC inhibitor, TSA for
24 h, on human primary adult and BJ1 foreskin fibroblasts,
cultured in chromatin remodeling medium (CRM). We
then assessed levels of transcripts of definitive endoderm
and early and late pancreatic endocrine markers, as well
as hepatocyte, skeletal muscle, endothelium, and pluripo-
tency marker genes. TSA/CRM significantly induced the
expression of the early endoderm marker genes, GATA4,
EOMES, E-CADHERIN, SOX17, FOXA2, andCXCR4, in both
cell populations, while induction of SOX7 and MIXL1 was
only seen in primary human fibroblasts (Figure 1(a) and
Figure S1A in Supplementary Material available online at
http://dx.doi.org/10.1155/2016/7654321). In addition, expres-
sion of the early and late pancreatic progenitor and endocrine
marker genes, PTF1A, HLXB9, NKX6.1, ISL1, ARX, and
MAFB, was observed in both cell populations, while PDX1
expression was only detected in primary human fibroblasts
treated cells (Figures 1(b)-1(c) and Figure S1B-C). Transcripts
formature endocrine pancreatic cells includingPAX4,NGN3,
INS, GCG, and SST were however not increased following
TSA/CRM culture (Figure 1(c) and Figure S1C). Transcripts
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Figure 1: Trichostatin A (TSA) treatment of primary adult fibroblasts induces transient definitive endoderm and pancreatic endoderm
markers. (a) qRT-PCRanalysis demonstrated induction of endodermal genes (GATA4, SOX7,MIXL1, EOMES, E-CADHERIN, SOX17, FOXA2,
and CXCR4 but not GSC) in TSA-CRM treated primary human fibroblast. (b) qRT-PCR analysis demonstrated induction of pancreatic
endoderm genes (PTF1A, PDX1, HLXB9, and NKX6.1 but not SOX9, PAX6, and NEUROD1) in TSA-CRM treated primary human fibroblast.
(c) qRT-PCR analysis demonstrated induction of pancreatic endocrine genes (ISL1, ARX, andMAFB but not PAX4, NGN3, MAFA, INS, SST,
andGCG) in TSA-CRM treated primary humanfibroblast. (d) qRT-PCR analysis demonstrated that hepatocyte genes (ALB andHNF4A) were
not induced except for AFP. (e) qRT-PCR analysis demonstrated induction of mesoderm lineage genes (MYOD1 and FLK1 but not TIE-2 and
VE-CADHERIN) in TSA-CRM treated primary human fibroblast. (f) qRT-PCR analysis demonstrated no induction of pluripotency genes
(OCT4, SOX2, and NANOG) expression in TSA-CRM treated primary human fibroblast. Black bar, CRM treated primary human fibroblast
cells; light grey bar, DMSO-CRM primary human fibroblast treated cells; dark grey bar, 100𝜇MTSA-CRM treated primary human fibroblast
cells. Gene expression is shown relative to the housekeeping gene GAPDH. Data represent the mean ± SEM (standard error of mean) of three
independent experiments. Statistical significance tests were performed between TSA treated versus untreated fibroblast and TSA treated
versus DMSO treated fibroblast. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 by unpaired 2-tailed Student’s 𝑡-test. NS, not significant.
for the hepatocyte marker genes, ALB, AFP, and HNF4A
(Figure 1(d) and Figure S1D), were not expressed. We also
assessed the effect of TSA/CRMon expression ofmesodermal
lineage transcripts and found an increase in MYOD1 and
FLK1 expression but not the endotheliummarker genes TIE2
and VE-CADHERIN (Figure 1(e) and Figure S1E). Pluripo-
tency marker genes OCT4, SOX2, and NANOG (Figure 1(f)
and Figure S1F) were not induced. When the remodeling
medium was removed, expression of the pancreatic endoder-
mal genes was not maintained.
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3.2. Combined Treatment of Fibroblasts with 5AZA and TSA
Did Not Result in Further Increased Expression of Definitive
Endoderm and Pancreatic Endocrine Genes. To test if com-
bination of DNA methylation modification and inhibition
of HDAC would induce a significant transdifferentiation of
fibroblasts to endocrine pancreas, we next cultured primary
adult fibroblasts and BJ1 fibroblast cells in CRM supple-
mented for 2 days with 3 or 5𝜇M 5AZA for 48 hours,
followed by TSA for 24 hours. However, as significant cell
deathwas seenwith 5AZAat 5𝜇Mormore, studieswere done
using 3𝜇M 5AZA. Treatment for 2 days with 5AZA induced
subtlemorphological changes. In comparisonwith the typical
elongatedmorphology of untreated fibroblasts, 5AZA treated
cells had a more rounded shape without long processes.
5AZA also decreased cell proliferation, which was analyzed
by cell counting (data not shown). Following treatment with
TSA on day 3, the cells appearedmore flattened with granular
cytoplasm and larger nuclei possibly due to more relaxed
chromatin structure. Cell proliferation remained stable upon
exposure to TSA.
We next assessed the effect of 5AZA combined with
TSA on transcript expression as described for TSA only
studies above. By contrast, following treatment with 5AZA
followed by TSA, endodermal early and late pancreatic
endocrine progenitor marker genes were induced in both
primary and BJ1 foreskin fibroblasts (Figures 2(a)–2(c) and
Figures S2A–C). However, as with TSA only in this case also,
mature pancreatic endocrine marker genes were not induced
(Figure 2(c) and Figure S2C). As was seen for cultures treated
with TSA alone, hepatocyte marker genes were not induced
(Figure 2(d) and Figure S2D), but the mesodermal markers,
MYOD1 and FLK1, were induced (Figure 2(e) and Figure
S2E). Other mesodermal (Figure 2(e) and Figure S2E) and
pluripotency marker genes (Figure 2(f) and Figure S2F) were
also not induced. Again, when the epigenetic modifiers were
removed, expression of the pancreatic endodermal genes was
not maintained. Finally, we also demonstrated that, aside
from TSA, CRM was essential for induction of endodermal
and pancreatic endodermal transcripts and that induction
of the pancreatic endoderm genes was more efficient when
early passage cells were used. We next assessed if combining
5AZA with TSA-CRM increases the expression level of
definitive endoderm and early and late pancreatic endocrine
progenitor transcripts. In both cell lines, induction of most,
albeit not all, endodermal and early and late pancreatic
marker genes was not improved by pretreatment of the cells
with 5AZA before addition of TSA-CRM (Figures S3-4A–
C). 5AZA pretreatment enhanced expression of the skeletal
muscle markerMYOD1 (Figure S3E) but not hepatocyte and
pluripotency marker genes (Figures S3-4D and F). Despite
the morphological changes observed following treatment
with 5AZA-CRM for 2 days, no induction of pancreatic or
other lineage specific markers was observed (Figures S5-6).
4. Discussion
We demonstrated that treatment of two different sources of
human fibroblasts with TSA in CRM induced expression
of endoderm lineage markers and pancreatic endoderm
markers known to be important for 𝛽-cell differentiation,
albeit at modest levels. By contrast, 5AZA did not induce
expression of endoderm and pancreatic endoderm mark-
ers though morphological changes occurred. However, the
induction resulting from treatment with TSA, or a com-
bination of 5AZA followed by TSA, was reversible and
disappeared upon removal of the epigenetic modifiers and
the chromatin remodeling medium. Interestingly, already
in 1977, Taylor and Johns demonstrated that 5AZA can
support transdifferentiation of mouse fibroblasts into skeletal
myoblasts by the master regulatorMyoD [29, 30] but did not
recognize the involvement of epigenetics.
In line with our studies, Pennarossa et al. [19] described
that culture of human fibroblasts with 5AZA resulted in
minimal induction of endodermal and pancreatic marker
genes. However, they demonstrated that such pretreatment
allows cells subsequently to differentiate into 𝛽-cells when
cultured in the presence of cocktails of growth factors
to induce pancreatic endoderm and subsequently mature
endocrine pancreatic cells. In a second study by the same
group [20], similar results were reported for pig fibroblasts,
where again they described that treatment with 5AZA alone
does not cause robust changes in endoderm and pancreatic
gene expression patterns but may change the epigenetic state
of fibroblasts such that they subsequently become susceptible
to growth factors that support pancreatic endocrine and 𝛽-
cell differentiation.
Another approach, described by Katz et al., combined
the use of TF overexpression followed by treatment of the
transduced cells on day 3 with a HDACi (Romidepsin) and
5AZA to transdifferentiate human dermal fibroblasts into 𝛽-
cells [21]. They demonstrated that Romidepsin could activate
some endocrine pancreas genes, whereas 5AZAalone did not.
This corroborates our observations that the HDAC inhibitor
TSA can induce endoderm and pancreatic marker genes.
They further found that PDX1 was only minimally induced
despite the fact that the combination of Romidepsin and
5AZA could induce a number of markers of pancreatic endo-
derm and more mature pancreatic cells. Only when overex-
pression of PDX1 was combined with the epigenetic modi-
fiers, human fibroblasts could be reprogrammed to 𝛽-cells.
We speculate that TSA combinedwithCRMmay induce a
“versatile” epigenome surrounding endodermal and pancre-
atic genes but cannot induce full reprogramming. Full repro-
gramming may require that we combine this approach with
transduction of a limited number of key pancreatic TFs (like
PDX1) or culture in growth factor cocktails known to allow
differentiation of PSC to 𝛽-cells. Aside from the HDACi,
TSA, CRM was also needed to induce the endodermal and
pancreatic genes. Which factor from CRM has this added
epigenetic effect is currently still unclear, but it might be L-
Ascorbic Acid, as this compound has been shown to enhance
reprogramming via the induction of ten-eleven translocation
(TET) hydroxylase dependent DNA demethylation [31–33].
5. Conclusion
In summary, we described an optimized schedule for treat-
ment of human fibroblasts with epigenetic modifiers to
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Figure 2: 5-Azacytidine (5AZA) and Trichostatin A (TSA) treatment of primary adult fibroblast induces transient definitive endoderm and
pancreatic endodermmarkers. (a) qRT-PCR analysis demonstrated induction of endodermal genes (GATA4,MIXL1, EOMES, E-CADHERIN,
SOX17, and CXCR4 but not SOX7, GSC, and FOXA2) in 5AZA + TSA-CRM treated primary human fibroblast cells. (b) qRT-PCR analysis
demonstrated induction of pancreatic endoderm genes (HNF1B, PDX1, HLXB9, PAX6, and NKX6.1 but not SOX9, PTF1A, and NEUROD1)
in 5AZA + TSA-CRM treated primary human fibroblast cells. (c) qRT-PCR analysis demonstrated induction of the pancreatic endocrine
genes (ISL1, ARX, MAFB, and MAFA but not PAX4, NGN3, INS, SST, and GCG) in 5AZA + TSA-CRM treated primary human fibroblast
cells. (d) qRT-PCR analysis demonstrated no induction of hepatocyte genes (ALB, AFP, and HNF4A) in 5AZA + TSA-CRM treated primary
human fibroblast cells. (e) qRT-PCR analysis demonstrated induction of mesoderm lineage genes (MYOD1 and FLK1 but not TIE-2 and VE-
CADHERIN) in 5AZA+TSA-CRM treated primary human fibroblast cells. (f) qRT-PCR analysis demonstrated no induction of pluripotency
genes (OCT4, SOX2, and NANOG) in 5AZA + TSA-CRM treated primary human fibroblast cells. Black bar, CRM treated primary human
fibroblast cells; light grey bar, DMSO-CRM treated primary human fibroblast cells; dark grey bar, 3 𝜇M 5AZA-CRM followed by 100𝜇M
TSA-CRM treated primary human fibroblast cells. Gene expression is shown relative to the housekeeping gene GAPDH. Data represent the
mean ± SEM (standard error of mean) of three independent experiments. Statistical significance tests were performed between 5AZA + TSA
treated versus untreated fibroblast and 5AZA + TSA treated versus DMSO treated fibroblast. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗𝑝 < 0.001 by
unpaired 2-tailed Student’s 𝑡-test. NS, not significant.
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activate endocrine pancreatic marker genes. We demon-
strated that culture of adult human fibroblasts with TSA
combined with CRmedium induces expression of endoderm
and pancreatic endoderm genes but that this is a reversible
phenomenon. Treatment with TSA/CRM also induced some
mesoderm lineage markers MYOD1 and FLK1 in both
fibroblast cell lines. When treatment with 5AZA-CRM was
added before TSA-CRM treatment, an increase in mesoderm
lineage markers MYOD1 was seen beyond levels induced
by TSA-CRM, but 5AZA/CRM itself did not induce any
lineage marker expression. Hence, further maintenance in 𝛽-
cell-specifying conditions with or without forced expression
of exogenous TFs will be needed to eventually convert
fibroblasts to 𝛽-cells.
Additional Points
(1) Trichostatin A (TSA) treated fibroblasts with chro-
matin remodeling medium (CRM) are induced
towards definitive and pancreatic endoderm cell fate.
(2) TSA-CRMdid not affect expression of hepatocyte and
pluripotency markers but induced mesoderm lineage
markers, especiallyMYOD1 and FLK1.
(3) Pretreatment of fibroblasts with 5AZA-CRM prior to
TSA-CRM did not induce further increase in gene
expression over levels induced with TSA-CRM alone
for all markers tested.
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